Related references
Note: Only part of the references are listed.Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial
Joseph Pidala et al.
BLOOD (2020)
Effect of Itraconazole or Rifampin on Itacitinib Pharmacokinetics When Administered Orally in Healthy Subjects
April M. Barbour et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Mortality, length of stay and costs associated with acute graft-versus-host disease during hospitalization for allogeneic hematopoietic stem cell transplantation
Jingbo Yu et al.
CURRENT MEDICAL RESEARCH AND OPINION (2019)
α1-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease
John M. Magenau et al.
BLOOD (2018)
Ruxolitinib protects skin stem cells and maintains skin homeostasis in murine graft-versus-host disease
Shuichiro Takahashi et al.
BLOOD (2018)
Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM)
Peter Bader et al.
BONE MARROW TRANSPLANTATION (2018)
Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft versus-host disease
Jaebok Choi et al.
LEUKEMIA (2018)
Targeting IFNGR/IL6R or downstream JAK1/JAK2 to control GvHD
Kidist Ashami et al.
Oncotarget (2018)
A phase 3 randomized trial comparing inolimomab vs usual care in steroid-resistant acute GVHD
Gerard Socie et al.
BLOOD (2017)
Patterns of infection and infection-related mortality in patients with steroid-refractory acute graft versus host disease
I. Garcia-Cadenas et al.
BONE MARROW TRANSPLANTATION (2017)
Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis
John O. Mascarenhas et al.
HAEMATOLOGICA (2017)
Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis
John O. Mascarenhas et al.
HAEMATOLOGICA (2017)
Role of myeloid-derived suppressor cells in allogeneic hematopoietic cell transplantation
Brent H. Koehn et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2017)
The Hyperlipidemia Caused by Overuse of Glucocorticoid after Liver Transplantation and the Immune Adjustment Strategy
Xueqin Meng et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2017)
Natural Killer Cells in Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation
Federico Simonetta et al.
FRONTIERS IN IMMUNOLOGY (2017)
Safety and Efficacy of Infliximab Therapy in the Setting of Steroid-Refractory Acute Graft-versus-Host Disease
Fevzi E. Yalniz et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
Novel GM-CSF signals via IFN-γR/IRF-1 and AKT/mTOR license monocytes for suppressor function
Eliana Ribechini et al.
BLOOD ADVANCES (2017)
An early-biomarker algorithm predicts lethal graft-versus-host disease and survival
Matthew J. Hartwell et al.
JCI INSIGHT (2017)
Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases
Daniella M. Schwartz et al.
NATURE REVIEWS RHEUMATOLOGY (2016)
A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation
Pooja Khandelwal et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Combination Therapy with Inolimomab and Etanercept for Severe Steroid-Refractory Acute Graft-versus-Host Disease
Lenneke F. J. van Groningen et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Association of Cumulative Steroid Dose with Risk of Infection after Treatment for Severe Acute Graft-versus-Host Disease
Yayoi Matsumura-Kimoto et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Risk Factors for Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation with Umbilical Cord Blood and Matched Sibling Donors
Aleksandr Lazaryan et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Circulating CD14+HLA-DR-/low myeloid-derived suppressor cells in leukemia patients with allogeneic hematopoietic stem cell transplantation: novel clinical potential strategies for the prevention and cellular therapy of graft-versus-host disease
Jin Yin et al.
CANCER MEDICINE (2016)
A Refined Risk Score for Acute Graft-versus-Host Disease that Predicts Response to Initial Therapy, Survival, and Transplant-Related Mortality
Margaret L. MacMillan et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
Madan H. Jagasia et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Pharmacologic Inhibition of JAK1/JAK2 Signaling Reduces Experimental Murine Acute GVHD While Preserving GVT Effects
Cristiana Carniti et al.
CLINICAL CANCER RESEARCH (2015)
Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey
R. Zeiser et al.
LEUKEMIA (2015)
A microfluidic multiplex proteomic immunoassay device for translational research
Jing Cao et al.
CLINICAL PROTEOMICS (2015)
A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study
John E. Levine et al.
LANCET HAEMATOLOGY (2015)
How we treat chronic graft-versus-host disease
Mary E. D. Flowers et al.
BLOOD (2015)
Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease
Silvia Spoerl et al.
BLOOD (2014)
Reversal of CD8 T-Cell-Mediated Mucocutaneous Graft-Versus-Host-Like Disease by the JAK Inhibitor Tofacitinib
Naoko Okiyama et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)
Pharmacologic Blockade of JAK1/JAK2 Reduces GvHD and Preserves the Graft-Versus-Leukemia Effect
Jaebok Choi et al.
PLOS ONE (2014)
Critical Role of Jak2 in the Maintenance and Function of Adult Hematopoietic Stem Cells
Hajime Akada et al.
STEM CELLS (2014)
Immunosuppressive CD14+HLA-DRlow/neg IDO+ myeloid cells in patients following allogeneic hematopoietic stem cell transplantation
D. Mougiakakos et al.
LEUKEMIA (2013)
Treatment and management of graft-versus-host disease: improving response and survival
Catherine Garnett et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2013)
First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation
Paul J. Martin et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2012)
Risk factors for acute GVHD and survival after hematopoietic cell transplantation
Madan Jagasia et al.
BLOOD (2012)
Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study
John E. Levine et al.
BLOOD (2012)
IFNγR signaling mediates alloreactive T-cell trafficking and GVHD
Jaebok Choi et al.
BLOOD (2012)
What predicts high risk acute graft-versus-host disease (GVHD) at onset?: identification of those at highest risk by a novel acute GVHD risk score
Margaret L. MacMillan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria
Mary E. D. Flowers et al.
BLOOD (2011)
The role of cytokine signaling in the pathogenesis of cutaneous T-cell lymphoma
Ronnie M. Abraham et al.
CANCER BIOLOGY & THERAPY (2011)
The best endpoint for acute GVHD treatment trials
Margaret L. MacMillan et al.
BLOOD (2010)
Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation.
Ted A. Gooley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Sirolimus as Primary Treatment of Acute Graft-versus-Host Disease following Allogeneic Hematopoietic Cell Transplantation
Joseph Pidala et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
A Phase III Study of Infliximab and Corticosteroids for the Initial Treatment of Acute Graft-versus-Host Disease
Daniel R. Couriel et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
Endpoints for Clinical Trials Testing Treatment of Acute Graft-versus-Host Disease: A Joint Statement
Paul J. Martin et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network
Amin M. Alousi et al.
BLOOD (2009)
Graft-versus-host disease
James L. M. Ferrara et al.
LANCET (2009)
SOCS1 regulates CCR7 expression and migration of CD4+ T cells into peripheral tissues
Cheng-Rong Yu et al.
JOURNAL OF IMMUNOLOGY (2008)
Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease
John E. Levine et al.
BLOOD (2008)
Quality of life associated with acute and chronic graft-versus-host disease
S. J. Lee et al.
BONE MARROW TRANSPLANTATION (2006)
National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report
AH Filipovich et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2005)
Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial
SJ Lee et al.
BLOOD (2004)
A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease
L Cragg et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2000)
Share Paper
